Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus

BACKGROUND: Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria, María Eugenia, Gregori, Josep, Chen, Qian, García-Cehic, Damir, Llorens, Meritxell, de Ávila, Ana I., Beach, Nathan M., Domingo, Esteban, Rodríguez-Frías, Francisco, Buti, María, Esteban, Rafael, Esteban, Juan Ignacio, Quer, Josep, Perales, Celia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122477/
https://www.ncbi.nlm.nih.gov/pubmed/30176817
http://dx.doi.org/10.1186/s12879-018-3356-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122477/
https://www.ncbi.nlm.nih.gov/pubmed/30176817
http://dx.doi.org/10.1186/s12879-018-3356-6

Ejemplares similares